Greece
Test Circulating Tumor Cells are cells that have been released from a tumor and are circulating in the blood stream.
Not exact matches
Chicago, GenomeWeb — A new study by researchers from Memorial Sloan Kettering Cancer Center has demonstrated the predictive power of an AR - V7 protein expression
test using Epic Sciences» non-EPCAM-based
circulating tumor cell detection platform, which could help guide treatment decisions for men with metastatic castration - resistant prostate cancer.
Currently marketed for research use by Biofluidica, the
test's microfluidic channels use specific cancer antibodies to detect capture
circulating tumor cells.
Further research could
test these cancer stem
cell gene expression at the RNA and protein level in
circulating tumor cells and biopsies from patients on trial.
The role of rebiopsy and repeat analysis in the setting of post-treatment relapse, along with
testing of blood samples for mutations in
circulating tumor cells,
cell free
tumor DNA, or exosomes will be considered.
AR - V7 status was assessed through an experimental blood
test that measures AR - V7 mRNA in
circulating tumor cells.
Berkeley researchers isolated
circulating tumor cells from the blood of breast cancer patients, then used microscale physics to design a precision
test for protein biomarkers, which are indicators of cancer.
Houston Methodist researchers led by Dario Marchetti, PhD, have developed a blood
test that can identify
circulating tumor cells to predict breast cancer patients at risk for developing brain metastasis.
The findings, published in Gastroenterology, suggest that
circulating pancreas
cells (CPCs) seed the bloodstream before
tumors can be detected using current clinical
tests such as CT and MRI scans.
The
test detects so - called «
circulating tumor cells» (CTCs).